[Indicators of kidney damage in patients with multiple myeloma in the process of chemotherapeutic treatment.].

The purpose was to study the level of acute kidney injury markers cystatin C, KIM-1, IL-18, NGAL and L-FABR in the blood and urine of patients with the initially identified secreting multiple myeloma (MM) before and during chemotherapeutic treatment. The content of renal markers was examined by ELISA using commercial kits. The study included 23 patients with MM who received 6-8 21-day cycles of chemotherapy (CT) according to the VCD scheme.